A Welcome Addition to the Child and Adolescent ADHD Armamentarium

Video

This new medication is a huge leap forward for treating attention-deficit/hyperactivity disorder.

Ann Childress, MD, talks about Qelbree and the importance of its approval by the US Food and Drug Administration.

Dr Childress is a practicing psychiatrist with a subspecialty in child and adolescent psychiatry, clinical researcher, and president of the Center for Psychiatry and Behavioral Medicine, Inc. in Las Vegas.

Related Videos
ADHD
ADHD
“What we’re striving to do is conquer the unmet needs that are still here with treating ADHD, especially from a medication standpoint.”
Work takes up one-third of a patient’s life—it is important that we pay attention to it.
Related Content
What is new in research on opioid use disorder?

Opioid Use Disorder Research Roundup: April 19, 2024

April 19th 2024
Article
How to Talk to Teenagers About Substance Use

How to Talk to Teenagers About Substance Use

October 8th 2021
Podcast
Tris Pharma has formed the organization along with a licensing agreement with Braingaze for development, distribution of the technology.

Tris Digital Health Forms, Will Focus on Digital Diagnostic Platform for ADHD

April 18th 2024
Article
5 Personality Traits of Olympic Athletes

5 Personality Traits of Olympic Athletes

August 18th 2021
Podcast
From a promising new intervention for treatment-resistant depression to another look at the STAR*D controversy, here are highlights from the week in Psychiatric Times.

The Week in Review: March 25-29

March 30th 2024
Article
“The heart of the matter.” Researchers investigated the risk of cardiovascular disease associated with long-term ADHD medication use.

ADHD Medications and Long-Term Cardiovascular Risk

March 29th 2024
Article
© 2024 MJH Life Sciences

All rights reserved.